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Resistance to cancer chemotherapeutic treatment is a common phenomenon, especially in progressive disease. The generation of
cellular models of drug resistance has been pivotal in unravelling the main effectors of resistance to traditional chemotherapy at the
molecular level (i.e. intracellular drug inactivation, detoxifying systems, defects in DNA repair, apoptosis evasion, membrane
transporters and cell adhesion). The development of targeted therapies has also been followed by resistance, reminiscent of an
evolutionary arms race, as exemplified by imatinib and other BCR-ABL inhibitors for the treatment of chronic myelogenous
leukaemia. Although traditionally associated with the last stages of the disease, recent findings with minimally transformed
pretumorigenic primary human cells indicate that the ability to generate drug resistance arises early during the tumorigenic process,
before the full transformation. Novel technologies, such as genome profiling, have in certain cases predicted the outcome of
chemotherapy and undoubtedly have tremendous potential for the future. In addition, the novel cancer stem cell paradigm raises the
prospect of cell-targeted therapies instead of treatment directed against the whole tumour.
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Gilman and co-workers were the first to introduce chemotherapy
into clinical practice at the end of the Second World War when
they used nitrogen mustard to treat a patient with advanced
malignant lymphoma. After an initial regression of the disease, a
second course of therapy was given at a reduced dose due to the
toxicity of the treatment, with an associated lesser therapeutic
effect. By the time the third treatment was given, the tumour no
longer responded to the chemotherapeutic agent (Goodman et al,
1946). Since then, chemotherapy has been one of the main
therapeutic strategies in cancer treatment, but, to paraphrase Paul
Ehrlich, resistance has followed as a faithful shadow.
Chemotherapeutic strategies have used a variety of drugs and
hormonal agents that interfere with the basic machinery of the cell.
Subsequent improved understanding of the molecular alterations
present in the cancer cell has enabled the development of targeted
therapies for some forms of cancer. Interestingly, resistance
appears not only to traditional chemotherapy but also to targeted
therapies such as tamoxifen, which targets the oestrogen receptor
(ER) in breast cancer (Ali and Coombes, 2002); imatinib, which
targets the kinase activity of the translocated BCR-ABL in chronic
myelogenous leukaemia (CML) (Weisberg et al, 2007); or gefitinib,
which inhibits epidermal growth factor receptor (EGFR) kinase
(Engelman et al, 2007).
MECHANISMS OF RESISTANCE TO TRADITIONAL
CHEMOTHERAPY
Two main groups of factors contribute to the development of drug
resistance. The first group includes pharmacological and physio-
logical factors such as drug metabolism and excretion, inadequate
access of the drug to the tumour, inadequate infusion rate
and inadequate route of delivery. These are extremely important
issues not only in clinical practice but also fundamental in drug
development (Garattini, 2007). The second group includes cell- or
tissue-specific factors. The cytochrome P450 enzymes, a multigene
family of constitutive and inducible haem-containing oxidative
enzymes from the liver, play an important role in the metabolism
of a diverse range of xenobiotics and are often overexpressed in
a variety of solid tumours in which they can contribute to
drug resistance. Drug analogues of DNA precursors such as
5-fluorouracil and cytosine arabinoside require metabolic activa-
tion, and resistance can arise from modification of these activation
pathways. Altered topoisomerase I and II activity prevents drugs
such as doxorubicin, etoposide and camptothecin from binding
the topoisomerase–DNA complex, allowing the broken strands to
be repaired. Many anticancer drugs, such as platinum compounds,
alkylating agents and nitrosoureas, cause direct damage to the
structural integrity of the DNA, and resistance to these compounds
results from activation of DNA repair systems. Regulation of cell
death by evasion of apoptosis, necrosis, mitotic catastrophe
(Mansilla et al, 2006) or evasion of senescence (Dimri, 2005)
contributes towards drug resistance. In addition, the differential
expression of membrane proteins such as solute carriers, channels
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2002; Huang et al, 2004) have all been demonstrated to play an
important role in drug resistance. Although these mechanisms
have been clearly demonstrated in cell culture, their relevance with
the clinical outcome of chemotherapy is less clear (Cimoli et al,
2004; Uggla et al, 2007) and has only been demonstrated for some
of these mechanisms (Clarke et al, 2005).
MOLECULAR MECHANISMS OF RESISTANCE TO
TARGETED CHEMOTHERAPY
CML and imatinib
Chronic myelogenous leukaemia was the first human cancer to be
associated with a consistent chromosomal abnormality, the
Philadelphia chromosome, a translocation that juxtaposes the
30 sequence from the ABL1 proto-oncogene on chromosome 9
with the 50 sequence from the BCR gene on chromosome 22. The
resultant chimaeric BCR-ABL protein is a constitutively active
protein tyrosine kinase with an important role in the regulation of
cell growth (Melo and Barnes, 2007). Traditional therapy for CML
includes initial allogenic stem-cell transplantation and interferon-
a, followed by second-line treatment with hydroxyurea or busulfan
in non-responsive patients. Imatinib mesylate (formerly STI571;
Gleevec, Novartis, Basel, Switzerland) is a potent and highly
specific competitive inhibitor of the BCR-ABL tyrosine kinase.
Initially, it had a high rate of cytogenetic and haematologic
responses in patients with chronic-phase CML in whom previous
therapy had failed, and its use has revolutionised the management
and clinical expectations of CML patients. Unfortunately, not long
after its initial use, resistance to imatinib was demonstrated in
CML patients (Gorre et al, 2001). Approximately 50% of imatinib-
resistant CML patients carry a resistance-associated point muta-
tion in BCR-ABL, which interferes with imatinib binding. More
than 50 different resistance-associated point mutations have been
described to date. These findings have spurred the development of
second-generation BCR-ABL inhibitors such as BMS-354825,
which has a two-log increased potency relative to imatinib and
retains its inhibitory activity against 14 of 15 imatinib-resistant
BCR-ABL mutants tested (Shah et al, 2004). However, resistance to
some of these second-generation inhibitors, such as nilotinib and
dasatinib, has already been described. This indicates that the
potential for new drug-resistant point mutations in BCR-ABL
persists and justifies the continued development of more potent
BCR-ABL inhibitors (Weisberg et al, 2007). In the remaining
50% of imatinib-resistant patients with no BCR-ABL mutations,
BCR-ABL gene amplification or overexpression at the mRNA and
protein levels has been detected in clinical samples (Hochhaus et al,
2002). In addition, chromosomal aberrations, reduced intracellular
uptake of imatinib and the disease phase have all been implicated
in imatinib resistance (Nimmanapalli and Bhalla, 2002).
Breast cancer, tamoxifen, aromatase inhibitors and
trastuzumab
Breast cancer accounts for one in four of all female cancers,
making it by far the most common cancer in women in the western
world, where one in nine women will develop the disease at some
stage in their lives. Breast cancer treatment involves surgical
removal of the tumour, although this is ineffective if malignant
cells have escaped from the site of the primary tumour. Discovery
of the involvement of the ovarian hormone oestrogen and its
mechanism of action (Dickson and Lippman, 1995) paved the way
for the development of therapies for ER-positive patients that
inhibit oestrogen action. These therapies include tamoxifen, which
blocks the ER, and the oestrogen synthetase (aromatase) inhibitors
formestane and exemestane, which inhibit oestrogen synthesis
(Ali and Coombes, 2002). Despite the huge improvement in cancer
survival due to tamoxifen treatment, some patients relapse and
the use of sequential therapy with exemestane after 2–3 years
of tamoxifen treatment has improved disease-free survival, as
compared with the standard 5 years of tamoxifen treatment alone
(Coombes et al, 2004). The use of endocrine agents has markedly
reduced the number of deaths from breast cancer over the past
decades. However, in many cases, these therapies fail due to
recurrent endocrine-resistant tumours, and much effort is being
made to elucidate the mechanisms that underlie resistance to
endocrine therapies (Weinberg et al, 2005). Altered growth factor
signalling, notably EGFR (Schiff et al, 2005) and insulin-like
growth factor I receptor (IGF-IR) make a significant contribution
to the development of antioestrogen resistance, and these have
been reviewed recently (Baselga, 2006).
Up to 25% of patients diagnosed with breast cancer have
tumours that overexpress the EGFR-2 (HER2 or Erb B-2). HER2-
positive breast cancer is highly proliferative, difficult to treat and
confers a poor prognosis. Trastuzumab is a monoclonal antibody
targeted against the HER2 tyrosine kinase receptor. The majority
of patients with metastatic breast cancer, who initially respond to
trastuzumab, develop resistance within 1 year of treatment
initiation, and in the adjuvant setting, 15% of patients still relapse
despite trastuzumab-based therapy. Preclinical studies have
indicated several molecular mechanisms that could contribute to
the development of trastuzumab resistance. One major determi-
nant to resistance is increased signalling via the phosphatidylino-
sitol 3-kinase/Akt pathway. This results in the activation of
multiple receptor pathways, including HER2-related receptors and
non-HER receptors such as the IGF-IR, which appear to be
involved in a cross talk with HER2 in resistant cells (Berns et al,
2007). Alternatively, the loss of function of the tumour suppressor
PTEN, the negative regulator of Akt, results in an increase in
Akt signalling that leads to decreased trastuzumab sensitivity.
Decreased interaction between trastuzumab and its target receptor
HER2, which is due to steric hindrance of HER2 by cell-surface
proteins such as mucin-4 (MUC4), can block the inhibitory actions
of trastuzumab. Novel therapies targeted against these aberrant
molecular pathways offer hope that the effectiveness and duration
of response to trastuzumab can be greatly improved (Baselga,
2006; Nahta et al, 2006). As only about one-third of breast cancer
patients overexpressing HER2 respond to trastuzumab mono-
therapy, the identification of predictive biomarkers that can more
accurately select responders or non-responders is vital, not only to
improve its therapeutic index, but also to gain insight into the
molecular pathways involved in trastuzumab resistance and to
rationally design successful combination therapies.
THE ABILITY TO ACQUIRE DRUG RESISTANCE
ARISES EARLY DURING THE TUMORIGENESIS
PROCESS
The use of drug-resistant derivatives from human and other
mammalian cell lines has been of paramount importance for the
unravelling of many of the mechanisms of cancer drug resistance
highlighted above. However, they have proved less successful in
identifying the ultimate upstream regulators controlling these
events, and as such, how drug resistance arises is still unresolved.
Most cellular models of drug resistance have been developed from
transformed cell lines isolated from patients at a late stage in
cancer progression and whose tumours already exhibit a plethora
of karyotypic and physiologic abnormalities. Recently, several
groups have shown that it is possible to transform primary human
cells into fully tumorigenic cells by altering a small number of
defined pathways ex vivo. This cellular model of tumorigenesis
(Figure 1A) was first described by Hahn et al (1999) in human BJ
fibroblasts and embryonic kidney epithelial cells by expressing the
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SV40 large T-antigen (which binds and inactivates the tumour
suppressors p53 and pRb controlling the DNA repair and G1 cell
cycle checkpoints, respectively) and small t-antigen (which binds
and inactivates PP2A, a serine/threonine phosphatase involved in
several signalling pathways) and oncogenic ras. Primary human
epithelial cells from the mammary gland, prostate, ovary, trachea
and bronchia have now been transformed by introducing these or
similar sets of genes (Boehm and Hahn, 2005). Although somatic
p53 missense mutations are found in approximately 50% of human
cancers, the p53 pathway can also be inactivated in wild-type p53-
carrying tumours by p53 destabilisation via indirect mechanisms
such as MDM2/MDMX amplification. In addition, most wild-type
p53 types of cancer harbour alternative genetic alterations such as
mutations in APC in colon cancer, BRCA1 and BRCA2 in breast
cancer, and B-RAF in melanoma. As the p53 network is closely
linked to many other cellular pathways, it is likely that defects in
any of these pathways could alter p53 function (Soussi and Wiman,
2007).
The development of these minimally transformed cells has, for
the first time, allowed us to ask whether the capacity to develop
drug resistance arises before or after tumorigenic transformation,
and what is the minimum number of altered pathways required to
permit this event. In a series of progressively transformed
embryonic skin fibroblasts, it has been found that the minimum
number of genetic transformations necessary for a primary cell to
become drug resistant, in addition to hTERT expression, is
inactivation of the pathways controlled by p53 and pRb (Yagu ¨e
et al, 2007), confirming the pivotal roles of p53 and pRb in
deciding cell fate after drug treatment: senescence, apoptosis or
drug resistance (Dimri, 2005). Thus, in this cell model, the ability
to acquire drug resistance is not, as previously supposed, a late
event in tumorigenesis resulting from gross genetic instability, but
is intrinsic to the early steps in the tumorigenic pathway necessary
for transformation and can arise earlier than the full malignant
transformation (Figure 1B).
These findings with minimally transformed fibroblasts need to
be confirmed and extended to other epithelial cancer cell models
and to drugs with different modes of action to generalise their
relevance. However, they have opened the possibility to analyse the
ultimate controllers in the development of drug resistance.
CANCER STEM CELLS AND DRUG RESISTANCE
The cancer stem cell (CSC) hypothesis states that many, if not all,
cancers contain a minority population of transformed self-renew-
ing stem cells. These CSCs are responsible for sustaining the
tumour as well as giving rise to proliferating but progressively
differentiating cells constituting the tumour mass (Burkert et al,
2006; Li and Neaves, 2006). Cancer stem cells retain the essential
property of self-protection through the activity of multiple drug
resistance transporters such as ABCB1 (P-glycoprotein) and/or
ABCG2 (Breast Cancer Resistance Protein-1, BCRP1). The latter
is responsible for the side-population (SP) phenotype detected
in both normal and acute myeologenous leukaemia (AML)
haematopoietic stem cells (Wulf et al, 2001). As Mdr1a/1b
 / 
(P-glycoprotein-deficient) mice are able to display a normal
SP phenotype that disappears when Abcg2 is knocked down
(Zhou et al, 2002), expression of ABCG2 and Hoechst 33342 efflux
are two of the best markers of these cells. To date, the existence
of CSCs has been demonstrated in AML and CML, in brain
and gastrointestinal tumours, and in lung and breast cancer
(de Jonge-Peeters et al, 2007).
A connection between CSCs and drug resistance is thought to
exist due to the expression of many of the membrane transporters.
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Figure 1 Cellular model of tumorigenesis and pretumorigenic drug resistance. (A) This model was first described by Hahn et al (1999) in human BJ
fibroblasts and embryonic kidney epithelial cells. Normal cells are transformed by expressing the catalytic subunit of telomerase (to avoid replicative
senescence), SV40 LT (which binds and inactivates the tumour suppressors p53 and pRb controlling the DNA repair and G1 cell-cycle checkpoints,
respectively) and ST (which binds and inactivates PP2A, a serine/threonine phosphatase involved in several signalling pathways) proteins and oncogenic ras.
Since then, the model has been validated by transforming primary epithelial cells from breast, prostate, ovary and lung (Boehm and Hahn, 2005). (B)
Complete tumorigenic transformation is not a prerequisite for the acquisition of drug resistance. When a series of pretumorigenic and minimally transformed
tumorigenic cells derived from human embryonic skin fibroblasts are treated with doxorubicin, drug-resistant cells can be obtained from fully tumorigenic as
well as pretumorigenic cells. Cells at the early stages of transformation, that is, those in which hTERT (telomerase) has been ectopically expressed, do not die
due to the action of the drug, but become senescent (drug-induced sencescence). Disruption of the pathways controlled by the tumour suppressors p53
and pRb is necessary and sufficient to set the conditions for the acquisition of drug resistance. The diagram is based on data from Yagu ¨e et al (2007).
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incorporating the CSC paradigm (Dean et al, 2005; Donnenberg
and Donnenberg, 2005). According to the acquired resistance
stem-cell model, CSCs, which express drug transporters, are
present in the original tumour mass and survive chemotherapy,
whereas the committed but variably differentiated cells are killed.
These cells reform a heterogeneous drug resistant tumour
composed of CSCs and a committed but variably differentiated
offspring. In addition, mutation in the surviving CSCs can arise
expanding the drug-resistant phenotype. However, the CSC
hypothesis does not account for resistance that develops in certain
cancers following chemotherapy in which all cancer cells (not just
stem cells) become resistant. Such intrinsic drug resistance is in
many cases, such as colon and liver cancer, due to the function of
ABC transporters, which are already highly expressed in the
healthy tissues.
DRUG RESISTANCE IN THE CLINIC AND ITS
REVERSAL
Cell culture systems and animal models have been pivotal in
defining the main molecular and cellular mechanisms responsible
for the drug-resistance phenotype. With them it has been relatively
straight forward to demonstrate that a particular molecule (i.e.
P-glycoprotein or p53) is the effector of drug resistance, due to
the ease of performing knockout or ectopic expression experi-
ments. However, the situation in the clinic is far more complicated,
not only because of the lack of sensitivity and the absence of
appropriate detection techniques from clinical samples, but also
because the association of a particular drug-resistance effector
does not necessarily correlate with an alteration in the chemo-
therapy response (Cimoli et al, 2004). Despite this, a negative
correlation has been unequivocally demonstrated between
P-glycoprotein expression and chemotherapy response in AML
(Gottesman et al, 2002) and breast cancer (Clarke et al, 2005).
Since the discovery of P-glycoprotein in the early 1980s, most
agents tested for the reversal of multidrug resistance in the clinic
have aimed at inhibiting P-glycoprotein function. The first
generation of P-glycoprotein inhibitors included verapamil,
quinine and cyclosporine, which were already approved for
other medical purposes. Although these compounds proved
to be ineffective or toxic at the doses required to attenuate
P-glycoprotein function, some clinical trials indicated
that modulation of P-glycoprotein function could be achieved
(Gottesman et al, 2002). This encouraged the development of a
second-generation of modulators, such as the cyclosporine
analogue PSC-833 (Valspodar), aimed at avoiding the toxic side
effects seen in the first generation. However, the development of
second-generation inhibitors has now been discontinued, mainly
due to their limited success in clinical trials (PSC-833 induced
pharmacological interactions that limited drug clearance and
metabolism of the chemotherapeutic agent, thereby elevating
plasma concentrations beyond acceptable toxicity). Third-genera-
tion inhibitors have been designed for low pharmacokinetic
interaction, and inhibition of cytochrome P450 3A has been
avoided with compounds such as laniquidar (R101933), oc144-093
(ONT-093), zosuquidar (LY335979), elacridar (GF-120918) and
tariquidar (XR9576). A further generation of inhibitors acts on
a broader range of ABC transporters. These include biricodar
(VX-710) and GF-120918, which modulate not only P-glycoprotein
but also MRP1 and ABCG2, respectively. Most clinical trial end
points have not been analysed yet; for an extended discussion
of P-glycoprotein inhibitors in the clinic see Szakacs et al (2006).
There are many different possible reasons for the failure of phase
III clinical trial targeting P-glycoprotein. These include multifactorial
mechanisms of resistance, toxicity of the inhibitors and unfavourable
pharmacological interactions, as well as a poor clinical trial design.
The latter is exemplified by the phase III clinical trial using
tariquidar as an adjunctive treatment in combination with first-line
chemotherapy for patients with non-small cell lung carcinoma, in
which there is no strong evidence to suggest that in this type of
cancer, P-glycoprotein is expressed to a significant extent (Szakacs
et al, 2006). Even AML patients, in which P-glycoprotein expression
affects the outcome of chemotherapy, are not routinely phenotyped,
and current efforts to develop simple, intercentre reproducible
protocols to detect P-glycoprotein in AML blasts have been
developed (Pallis et al, 2005). In such a way, trial organisers can
have the choice of whether to give P-glycoprotein modulators to an
unsorted cohort or to P-glycoprotein-positive patients only.
Other alternative approaches to target P-glycoprotein-mediated
drug resistance could involve the development of agents to interfere
with any one of the regulatory steps in P-glycoprotein expression:
transcription, mRNA turnover, translation, protein processing and
turnover. Of these, the only one under trial in soft tissue sarcoma
(currently phase II) is ecteinascidin 743, a natural product isolated
from the marine organism Ecteinascidia turbinate. Ecteinascidin
743 interferes with the activation of ABCB1 via the stress-responsive
enhanceosome complex (Le Cesne et al,2 0 0 5 ) .
Genome-wide expression profiling has been used to study drug
resistance, and the foreseeable complexity of their mechanisms has
been revealed. In addition to the corroboration of traditionally
associated genes, these studies have given new insight into the
regulatory networks controlling drug resistance (Turton et al,2 0 0 1 ) .
The most interesting application of the novel genomic technologies
has been in the clinical arena, where molecular signatures have been
used not only to characterise neoplastic transformation (Sotiriou et al,
2003) and resistant tumours (Jansen et al, 2005) but also, and most
importantly, to predict the outcome of chemotherapy (Alaoui-Jamali
et al, 2004).Whether these novel technologies will gain acceptance in
the routine diagnosis of cancer will depend greatly on whether their
current costs can be reduced (Sotiriou and Piccart, 2007).
CONCLUSIONS AND PERSPECTIVES
Many years have passed since the first description of cancer as
an evolutionary process (Nowell, 1976). With the establishment of
the CSC paradigm, new insights into the relative high frequency of
cancer in humans and the pitfalls of many cancer treatments have
been put forward based on Darwinian selection (Greaves, 2007).
Although there are many differences between neoplastic and
organismal evolution, the lack of cellular controls to maintain
genomic stability, telomere length, repair of DNA damage or cell
cycle regulation discussed above set up the conditions for genetic
diversity as a source of clonal evolution. Treatment with
chemotherapeutic agents promotes an evolutionary arms race
exemplified by the resistance to imatinib and the generation of
novel derivatives in CML. Studies using cell model systems have
shown that chemotherapy resistance is intrinsic to the tumorigen-
esis process and can even arise before malignant transformation.
Thus, possible solutions lie in the development of novel
approaches, based mainly on immunological and gene therapy
techniques, aiming to at least partially restore some of the normal
cellular controls, although cancer gene therapy is still in its
infancy. Whether these or other still-to-come therapies will allow
us to say in future years, paraphrasing the Borg from Star Trek,
‘Resistance is futile’ is difficult to foresee, but as Captain Jean-Luc
Picard stated ‘Things are only impossible until they’re not’.
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